P osterior amorphous corneal dystrophy (PACD) is a rare autosomal dominant corneal dystrophy and has been reported in only 11 families to date. [1] [2] [3] [4] [5] [6] [7] [8] [9] Characteristic clinical features include partial or complete posterior lamellar corneal opacification, decreased corneal thickness (typically Ͻ500 m centrally), and average corneal curvature Ͻ41 D. 3, 4, 8, 9 Other reported manifestations include iris abnormalities, such as iridocorneal adhesions, correctopia, and iris atrophy. 8, 9 Even though subtle endothelial changes have been reported in some patients, [7] [8] [9] corneal endothelial function is not typically affected, 4, 7, 8 and most affected patients retain good corrected vision throughout their lives. Light and electron microscopic examinations of the corneas in affected patients have revealed an irregular arrangement of the collagen fibrils in the posterior corneal stromal lamellae and the presence of an abnormal collagenous layer either within Descemet's membrane or between it and the corneal endothelium. 6, 7 Because no intracellular or extracellular deposits have been detected with the use of hematoxylin-eosin, Masson trichrome, or Alcian blue stains, posterior stromal opacification has been attributed to the disorganization of the posterior stromal lamellae, similar to the cause of the stromal opacification in congenital hereditary stromal dystrophy.
Many of the clinical features associated with PACD are also associated with cornea plana, such as corneal flattening (with associated high hyperopia), iridocorneal adhesions, and iris atrophy. Although the genetic basis of the autosomal dominant form of cornea plana (CNA1 [Mendelian Inheritance in Man (MIM) 121499]) remains unknown, the autosomal recessive form (CNA2 [MIM 217300]) has been associated with mutations in the keratocan gene (KERA [MIM 603288]). 10 -15 We sought to identify the genetic basis of PACD through genomewide linkage analysis and screening of positional and functional candidate genes KERA, lumican (LUM [MIM 600616]), decorin (DCN [MIM 125255]), and epiphycan (EPYC [also known as DSPG3; MIM 601657]) in affected and unaffected members of a large, previously unreported family with PACD. We further characterized the clinical and histopathologic features of PACD through description of the anterior segment clinical findings in affected members of this fivegeneration pedigree and by light and electron microscopic examinations of an excised corneal specimen.
MATERIALS AND METHODS
The researchers followed the tenets of the Declaration of Helsinki in the treatment of the subjects reported herein. Study approval was obtained from the Institutional Review Board at the University of California at Los Angeles (UCLA IRB 94 -07-243-23 and 94 -07-243-24).
Patient Identification and DNA Collection
After informed consent was obtained, a slit lamp examination was performed for each study participant to determine the affected status.
The diagnosis of PACD was based on the presence of one or more of the following clinical features in each eye: scleralization of the peripheral cornea; partial or complete posterior corneal lamellar haze; decreased central corneal thickness (Յ500 m); significant corneal flattening (average corneal curvature Ͻ38 D); or an iris abnormality, such as iris atrophy, coloboma, or correctopia. Blood was obtained from 37 subjects. For an additional 17 subjects for whom phlebotomy could not be performed or was refused, DNA was collected using buccal epithelial swabs (CytoSoft Cytology Brush; Medical Packaging Corporation, Camarillo, CA) and saliva collection kits (Oragene; DNA Genotek Inc., Kanata, ON, Canada). DNA was prepared from peripheral blood leukocytes and buccal epithelial cells using DNA kits (PaxGene [Qiagen, Valencia, CA] and DNA Blood Mini Kits [Qiagen], respectively).
Genomewide Linkage Analysis, PCR Amplification, and Genotyping
Genomewide linkage analysis was performed using a linkage mapping set (MD-10; Applied Biosystems, Foster City, CA) consisting of 400 microsatellite markers that span the entire human genome at a 10 cM average marker density. Polymerase chain reaction (PCR) amplification of each marker was performed using a forward primer of each pair that was labeled with the fluorescent dye tag 6-FAM, VIC, or NED. Reactions were carried out using 15 ng preamplified genomic DNA (amplified using a DNA amplification kit [GenomiPhi; GE Healthcare BioSciences, Piscataway, NJ]).
Genotyping was performed at the UCLA Sequencing and Genotyping Core facility. PCR fragments were analyzed on capillary DNA analyzers (ABI-3700 and 3ABI-730; Applied Biosystems). Each run included two positive control samples (individual 2 in CEPH family 1347; Coriell Institute, Camden, NJ). Genotype calling was performed using Applied Biosystems software (Genotyper and GeneMapper). All genotypes were verified by human inspection in two independent readings.
Fine-Mapping Linkage Analysis, PCR Amplification, and Genotyping
Thirty microsatellite markers spanning an 18-cM region of chromosome 8 surrounding marker D8S1784 and 40 microsatellite markers spanning an 18-cM region of chromosome 12 surrounding marker D12S351 were selected from the National Center for Biotechnology Information (NCBI) public database. Locations of the markers were determined by referencing physical (NCBI Map Viewer; NCBI build 37.1) and genetic (Marshfield Clinic Center for Human Genetics) maps.
PCR amplification of all markers was performed using primer sequences obtained from the uniSTS section of the NCBI database. The forward primer of each pair was labeled with one of the fluorescent dye tags-6-FAM, VIC, or NED-from Applied Biosystems. Each reaction was carried out in a 25-L mixture containing 60 to 70 ng preamplified genomic DNA (amplified with GenomiPhi DNA amplification kit from Amersham Biosciences Corp., Piscataway, NJ), 0.25 L each primer (10 pM/L), 0.5 U Taq DNA polymerase, and 2.5 L 10ϫ PCR buffer (Sigma-Aldrich Co., St. Louis, MO). Thermal cycling was performed (iCycler; Bio-Rad, Hercules, CA) under the following conditions: initial denaturation for 5 minutes at 95°C, 30 cycles at 94°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 seconds, and a final extension for 5 minutes at 72°C.
Genotyping was performed at the UCLA Sequencing and Genotyping Core. PCR fragments were analyzed on capillary DNA analyzers (ABI 3700 and 3730; Applied Biosystems). Each run included two positive control samples (individual 2 in CEPH family 1347; Coriell Institute). Genotype calling was performed using Applied Biosystems (Genotyper and GeneMapper) software. All genotyping was performed blind to family structure and was verified by human inspection in two independent readings.
Statistical Analysis
Before the performance of linkage analysis, possible genotyping inconsistencies were evaluated using SimWalk 2.91. 16 All genotypes with a posterior probability of mistyping greater than 0.5 were reevaluated by review of the raw genotype data. If the possible mistyping was not resolved by review, the suspect genotypes were set to unknown. On reevaluation of the raw data, 21 genotypes were changed, and 118 genotypes were set to unknown, representing a mistyping rate of 0.55%.
Single-point linkage analysis was performed using Mendel 10, 17 and multipoint linkage analysis was performed using SimWalk 2.91. For both single-point and multipoint analyses, an autosomal partial-dominance model was used with a disease allele frequency of 0.001, a phenocopy rate of 0.001, and penetrance rates of 0.8 for heterozygotes and 0.999 for homozygotes. Haplotype analysis was performed using SimWalk 2.91.
Candidate Gene Screening
PCR Amplification. Using DNA from affected and unaffected individuals (II-10, III-4, III-13, III-15, IV-3, and IV-9 in Fig. 1 ), the coding regions of the KERA, LUM, DCN, and EPYC genes were amplified by PCR using custom-designed primers (sequences available on request). All primers were designed so that they would bind to intronic segments 60 to 80 nucleotides on either side of the intron-exon boundary to ensure complete reading of the exons. Each reaction was carried out in a 25-L mixture containing 50 mM Tris-HCl (pH 9.0, 25°C), 20 mM NH 4 Cl, 2.5 mM MgSO 4 , 200 M each dNTP, 0.5 M betaine, 2.5 L DMSO, 150 mM trehalose, 0.002% Tween-20, 0.12 M each primer, 0.5 U genomic DNA polymerase (REDTaq; Sigma-Aldrich), and approximately 60 ng genomic DNA. Thermal cycling was then performed (iCycler Thermal Cycler; Bio-Rad).
DNA Sequencing. PCR products were purified by incubating 15
to 30 ng DNA with 5 U exonuclease I and 0.5 U shrimp alkaline phosphatase (USB Corp., Cleveland, OH) for 15 minutes at 37°C. After inactivation of the nucleases (80°C for 15 minutes), sequencing reactions were performed by the addition of 1 L reaction mix (BigDye Terminator Mix v3.1; Applied Biosystems), 1 L dilution buffer (SeqSaver; Sigma-Aldrich), and 0.2 L primer solution (10 pM/L). Samples were denatured at 96°C for 2 minutes, then cycled 25 times at 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 4 minutes. Unincorporated nucleotides were removed using a reagent and a solid-phase reversible immobilization (SPRI) plate (CleanSeq; Agencourt Bioscience Corporation, Beverly, MA) according to the manufacturer's instructions. Amplified DNA was then resuspended in 0.1 mM EDTA and analyzed on a genetic analyzer (ABI-3100; Applied Biosystems). Nucleotide sequences were read manually and with a software program (Mutation Surveyor v2.2; Softgenetics, State College, PA). The sequences were compared with the published cDNA sequence for KERA (NM_007035), LUM (NM_002345), DCN (NM_001920), and EPYC (NM_004950).
Light and Electron Microscopic Analysis
A corneal button, removed from one of the affected individuals (Fig. 1 , III-13) at the time of penetrating keratoplasty, was bisected. Half the button was fixed in 10% neutral-buffered formaldehyde and analyzed with light microscopy after staining with hematoxylin and eosin, Congo red, periodic acid-Schiff, Alcian blue, and colloidal iron stains. The other half was fixed in 2.5% glutaraldehyde and processed for transmission electron microscopy.
RESULTS

Clinical Characteristics
Twenty individuals in four consecutive generations were identified as affected, and 54 informative individuals were ascertained within the family (Fig. 1) . Each affected individual demonstrated posterior corneal stromal lamellar opacification that appeared either at or just anterior to Descemet's membrane (Fig. 2) . Opacification was incomplete in every affected individual, with areas of corneal lucency interspersed between the regions of swirling posterior lamellar corneal opacification. In each affected individual, the opacification was bilateral and symmetric, and appeared similar between both younger (Fig.  1 , generation V) and older (Fig. 1, generation II) (Fig. 2) . Most affected individuals demonstrated bilateral superior corneal scleralization (Fig. 2) , and several demonstrated iris abnormalities, including correctopia and iris coloboma (Fig. 2) . Two of the affected individuals required corneal transplantation for visually significant corneal opacification (Fig. 1, III-13 and IV-3) .
Fifteen of the affected individuals provided DNA for genetic analysis. Thirty-nine individuals who were examined and found to be unaffected also provided DNA for genetic analysis (Fig. 1 ).
Light and Electron Microscopy
Individual III-13 ( Fig. 1) underwent corneal transplantation at age 60 for visually significant corneal opacification. Light microscopic examination of the excised corneal specimen revealed irregularity of the posterior stromal lamellae. Although Descemet's membrane appeared mildly irregular, an abnormal collagenous layer was not identified either within or beneath it. Colloidal iron staining of the anterior and posterior corneal stromal regions was seen, although no staining was noted with Alcian blue, periodic acid-Schiff, or Congo red (Fig. 3) .
Electron microscopic examination revealed the presence of amorphous extracellular material between the stromal lamellae in the anterior cornea. Cystic membrane-bound structures were noted in the corneal endothelial cells, suggestive of dilated mitochondria (Fig. 3) .
Genomewide Linkage Analysis
Linkage analysis on the genomewide marker set yielded a large single-point log odds ratio (LOD) score of 3.42 (with ϭ 0) at marker D12S351 on chromosome 12q21.33. The next largest single-point LOD score was 2.68 (with ϭ 0) at marker D8S1784 on chromosome 8q22.3. No other single-point LOD score was above 2.5. The largest multipoint LOD score using the genomewide marker set was 3.82 at D12S351, the same marker that provided the highest single-point LOD score. Multipoint scores in this region identified an 11-cM support interval between flanking markers D12S1708 and D12S346. No positive LOD scores were identified on chromosome 8 with multipoint linkage analysis when using the genomewide marker set.
Fine Mapping in Chromosome 8q22.3 and 12q21.33 Regions
Fine mapping in the region of chromosome 8q22.3 generated a maximum single-point LOD score of 2.78 (with ϭ 0) at D8S1814. D8S1814 is only 370 kb from D8S1784, the location of the peak single-point LOD in this region in the genomewide scan. After including the fine mapping markers, the largest multipoint LOD score was 2.95 at D8S200, which is 2.1 Mb from D8S1814. Figure 4 graphs these results.
Fine mapping in the region of chromosome 12q21.33 generated a maximum single-point LOD score of 3.53 (with ϭ 0) at D12S1716, which is 5.1 Mb from D12S351, the location of the peak single-point LOD in this region in the genomewide scan. After including the fine mapping markers, the largest multipoint LOD score is 5.62 at D12S322. D12S322 is only 300 kb from D12S351. The multipoint scores in this region identify a 3.5-Mb (3.5 cM) linkage support interval between flanking markers D12S1812 and D12S95, roughly the entire chromosome band 12q21.33. Figure 5 graphs these results. The four functional candidate genes-KERA, LUM, DCN, and EPYCare within this 3.5-Mb linkage support interval on chromosome 12 (Fig. 6 ). Figure 1 , for whom no DNA was collected and whose haplotype could not be inferred from the rest of the pedigree, are not included in this figure.
Haplotype Analysis in Chromosome 8q22.3 and 12q21.33 Regions
Haplotype analysis of the chromosome 8q22.3 region found no consistent haplotype among the affected individuals. Given our genotyping results, Figure 7 shows the most likely haplotype configuration in the 10-cM interval from D8S1844 to D8S588. This interval includes the loci with the highest single-point and multipoint LOD scores on chromosome 8. Thirteen of the 19 analyzed affected individuals share a haplotype at all seven genotyped loci in this region. The shared haplotype did not extend beyond this interval. The other six affected individuals did not exhibit any consistent haplotypes in this region. Among all unaffected individuals, the entire consensus haplotype is seen only twice, in individuals III-02 and III-15 in Figure 7 .
Haplotype analysis of the chromosome 12q21.33 region showed a clear conserved haplotype segregating through the pedigree in almost all affected individuals. Given our genotyping results, Figure 8 shows the most likely haplotype configuration in the 10-cM interval from D12S1678 to D12S1051. This interval includes the loci with the highest single-point and multipoint LOD scores on chromosome 12. Eighteen of the 19 analyzed affected individuals share a haplotype at all 10 genotyped loci in this region. The shared haplotype did not extend beyond this interval. The remaining affected individual, III-10, does not share the lower half of this conserved haplotype. As seen in Figure 8 , the most likely configuration is individual III-10 does share the top half of the conserved haplotype. However, because of the extent of homozygosity in this region and some missing genotypes, it is also possible that III-10 did not inherit any part of this chromosomal region from the conserved haplotype in his father.
The conserved haplotype is found only once in each affected individual, supporting a dominant inheritance model for this trait. For all but two of the affected individuals, this haplotype originated in one of the pedigree founders, either I-1 or I-2. (Given that both founders have unknown affection status and were not genotyped, based on the current evidence they are equally likely to have introduced the haplotype into the pedigree.) The conserved haplotype was also observed in an affected married-in individual, III-11, and was then passed on to his affected son IV-7. (This suggests individual III-11 is genetically related to the other affected individuals, but that relationship is unknown.) The conserved haplotype was found in four unaffected individuals-III-09, IV-06, IV-14, and V-01-in Figure  8 , supporting a reduced penetrance inheritance model for this trait. All four unaffected individuals with the conserved haplotype are female.
KERA, LUM, DCN, and EPYC Screening
Three previously described single nucleotide substitutions were identified in the coding and untranslated regions of both KERA and LUM, two novel sequence variants were identified in the 5Ј untranslated region of KERA, and a novel synonymous substitution was identified in DCN. However, none of these sequence variants was considered pathogenic because none was found to segregate with the affected phenotype ( Table 1) . No sequence variants were identified in EPYC.
DISCUSSION
Since the initial discovery of the genetic basis of the TGBFI corneal dystrophies in 1997, vision science researchers have identified the genetic basis of approximately three-quarters of the corneal dystrophies. 18 PACD is one of the very few corneal dystrophies for which no genetic investigations have been published, most likely because of the rarity of the disorder; only 38 affected individuals from 11 families with PACD are reported in the literature. [1] [2] [3] [4] [5] [6] [7] [8] [9] We performed a microsatellitebased genomewide linkage analysis on a large family with 20 PACD affected individuals and identified two potential genetic loci for PACD. The genomewide analysis found significant evidence for linkage to chromosome 12q21.33 (LOD score Ͼ3.3) and suggestive evidence for linkage to chromosome 8q22.3 (LOD score 2.2-3.3). Fine mapping the chromosome 8q22.3 region did not result in evidence for significant linkage with either single-point or multipoint analysis. Haplotype analysis of chromosome 8 did not yield a consistent haplotype across the affected individuals. However, fine mapping the chromosome 12q21.33 region resulted in an increase in the maximum multipoint LOD score to 5.62, well above the standard threshold for genomewide significant evidence for linkage. These results provide a 3.5-Mb linkage support interval for a locus influencing PACD between flanking markers D12S1812 and D12S95, roughly the entire chromosome band 12q21.33. Haplotype analysis of chromosome 12 showed a highly conserved ancestral haplotype shared among the affected individuals, consistent with the linkage support interval.
KERA, the keratocan gene, is 1 of 11 genes that have been mapped to the 3.5-Mb linkage support interval in 12q21.33 (Human Genome Browser; NCBI build 37.1). Mutations in KERA have been shown to cause CNA2, the autosomal recessive form of cornea plana. 10 -15 Given the presence of many clinical features that are common to both cornea plana and PACD, KERA was selected as a candidate gene for PACD even before results of the genomewide linkage analysis were obtained. The demonstration of significant evidence of linkage of a PACD locus to the region of chromosome 12 to which KERA had previously been mapped further implicates a possible role for KERA (or a nearby functionally related gene) in the pathogenesis of PACD. Located adjacent to KERA on chromosome 12 are genes LUM, DCN, and EPYC, encoding three other members of the small leucine-rich proteoglycan (SLRP) family, lumican, decorin, and epiphycan, respectively. Proteoglycans, which modulate collagen fibril development and are involved in the maintenance of corneal clarity, consist of core proteins, such as keratocan, lumican, and decorin, bound to glycosaminoglycans, which form the ground substance of the cornea. 19 Interference with the function of the genes encoding the SLRPs leads to corneal opacification, as has been demonstrated in LUM-deficient mice 20 and in patients with congenital hereditary stromal dystrophy, which has been shown to be secondary to mutations in DCN. 21, 22 Thus, because the products of these genes have been shown to regulate corneal transparency and are all located within the linkage support interval, the coding region of each was screened in the same affected and unaffected individuals who had been screened for coding region mutations in KERA.
Although no coding region mutations were identified in KERA, LUM, DCN, and EPYC, it is still possible that one of these genes is involved in the pathogenesis of PACD. Only six genes have been mapped to the 1.2-Mb candidate interval for CNA1: KERA, LUM, DCN, EPYC, and two predicted genes, chromosome 12 open-reading frame 37 (C12orf37) and chromosome 12 open-reading frame 12 (C12orf12) (NCBI Map Viewer; NCBI build 37.1). 23 Therefore, it seems surprising that coding region mutations have not been identified in KERA, LUM, DCN, or EPYC in families with CNA1. 10, 15 However, given the significant phenotypic similarities between CNA1 and PACD and the location of KERA, LUM, DCN, and EPYC within the linkage support interval for each, these genes remain attractive positional and functional candidate genes for both conditions. Large-scale resequencing of the chromosomal region containing KERA, LUM, DCN, and EPYC is planned to exclude the possibility of a pathogenic copy number variant or a noncoding mutation that affects the function of the encoded protein product of one of the four genes through, for example, alteration of expression and exon skipping. We also encourage investigators who have reported families with posterior amorphous corneal dystrophy to perform fine mapping of the chromosome 12q21.33 candidate locus region using the same markers we did to demonstrate the replication of linkage to this locus and to further narrow the candidate interval through haplotype analysis.
